社区获得性共感染在 2019 年冠状病毒病中的作用：一项回顾性观察研究。
Community-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience.
机构信息
Section of Infectious Disease and Global Health, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA.
出版信息
Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. doi: 10.1093/cid/ciaa902.
Abstract
Community-acquired coinfection in coronavirus disease 2019 (COVID-19) is not well defined. Current literature describes coinfection in 0-40% of COVID-19 patients. In this retrospective report, coinfection was identified in 3.7% of patients and 41% of patients admitted to intensive care (P < .005). Despite infrequent coinfection, antibiotics were used in 69% of patients.
摘要
社区获得性合并感染在 2019 年冠状病毒病（COVID-19）中尚未明确界定。目前的文献描述 COVID-19 患者中有 0-40%合并感染。在本回顾性报告中，3.7%的患者和 41%的重症监护病房（ICU）患者被确定为合并感染（P<.005）。尽管合并感染并不常见，但抗生素仍在 69%的患者中使用。
相似文献
1
Community-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience.
Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. doi: 10.1093/cid/ciaa902.
2
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
3
A Retrospective Study of Coinfection of SARS-CoV-2 and Streptococcus pneumoniae in 11 Hospitalized Patients with Severe COVID-19 Pneumonia at a Single Center.
Med Sci Monit. 2020 Nov 14;26:e928754. doi: 10.12659/MSM.928754.
4
Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England.
Clin Infect Dis. 2021 Mar 1;72(5):e65-e75. doi: 10.1093/cid/ciaa1728.
5
Coinfection and Other Clinical Characteristics of COVID-19 in Children.
Pediatrics. 2020 Jul;146(1). doi: 10.1542/peds.2020-0961. Epub 2020 May 6.
6
Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study.
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1184-1193. doi: 10.1017/ice.2021.341. Epub 2021 Jul 26.
7
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.
J Epidemiol Glob Health. 2020 Sep;10(3):214-221. doi: 10.2991/jegh.k.200806.002.
8
Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic.
Ann Intern Med. 2020 Aug 18;173(4):304-305. doi: 10.7326/M20-2189. Epub 2020 May 7.
9
Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study.
Liver Int. 2021 Apr;41(4):720-730. doi: 10.1111/liv.14774. Epub 2021 Jan 10.
10
SARS-CoV-2-induced immunodysregulation and the need for higher clinical suspicion for co-infection and secondary infection in COVID-19 patients.
J Microbiol Immunol Infect. 2021 Feb;54(1):105-108. doi: 10.1016/j.jmii.2020.08.016. Epub 2020 Sep 8.
引用本文的文献
1
A Rare Fatal Case of COVID-19 Co-Infection with Community-Acquired Methicillin-Resistant Staphylococcus Aureus in a Diabetic Patient.
Infect Drug Resist. 2025 Apr 17;18:1935-1939. doi: 10.2147/IDR.S512885. eCollection 2025.
2
Initial Empirical Antibiotic Treatment in Patients with COVID-19 is Associated with Excess Adverse Drug Reactions without Clinical Benefit.
Turk J Pharm Sci. 2025 Jan 10;21(6):489-498. doi: 10.4274/tjps.galenos.2023.44675.
3
Molecular pathogen profiling of COVID-19 coinfections.
BMC Infect Dis. 2024 Dec 19;24(1):1451. doi: 10.1186/s12879-024-10347-7.
4
Clinical characteristics of SARS-CoV-2 Omicron pneumonia in immunocompromised and immunocompetent patients: A retrospective cohort study.
Heliyon. 2024 Oct 9;10(20):e39044. doi: 10.1016/j.heliyon.2024.e39044. eCollection 2024 Oct 30.
5
Secondary Bacterial Infections in Critically Ill COVID-19 Patients Admitted in the Intensive Care Unit of a Tertiary Hospital in Romania.
J Clin Med. 2024 Oct 18;13(20):6201. doi: 10.3390/jcm13206201.
6
The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19.
EBioMedicine. 2024 Jul;105:105213. doi: 10.1016/j.ebiom.2024.105213. Epub 2024 Jun 21.
7
SARS-CoV-2 co-detection with influenza and human respiratory syncytial virus in Ethiopia: Findings from the severe acute respiratory illness (SARI) and influenza-like illness (ILI) sentinel surveillance, January 01, 2021, to June 30, 2022.
PLOS Glob Public Health. 2024 Apr 18;4(4):e0003093. doi: 10.1371/journal.pgph.0003093. eCollection 2024.
8
Antibacterial agents used in COVID-19: A systematic review and meta-analysis.
Environ Sustain (Singap). 2021;4(3):503-513. doi: 10.1007/s42398-021-00194-6. Epub 2021 Jun 7.
9
Clinical and immunologic features of co-infection in COVID-19 patients, along with potential traditional Chinese medicine treatments.
Front Immunol. 2024 Mar 21;15:1357638. doi: 10.3389/fimmu.2024.1357638. eCollection 2024.
10
Total Infectome Characterization of Respiratory Infections during the 2022-23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity.
Pathogens. 2024 Feb 29;13(3):216. doi: 10.3390/pathogens13030216.
Zotero 插件